News
Third Rock in $2bn drug-hunting pact with China's Funnel
New Chinese biotech Funnel has signed a $2bn-plus partnership with Third Rock Ventures, focused on using its AI platform to discover novel biologics.
News
UK's Oyster Tx rebrands and raises $60m for Alzheimer's R&D
UK start-up Oyster Therapeutics has raised $60m in first-round financing for its novel take on protein degraders, starting with tau in Alzheimer's.
News
MHRA grants Innovation Passports to three novel drugs
The MHRA has awarded Innovation Passports to three drugs that could offer a step forwards in treating lung cancer, Huntington's, and Alzheimer's.
R&D
Europe’s growing vector-borne disease threat: Are we keeping...
In Europe, diseases once largely associated with tropical or subtropical regions are becoming a more immediate concern.
News
argenx agrees Unnatural takeover deal worth up to $1.15bn
argenx has agreed its second acquisition of the year, buying macrocyclic peptide drug developer Unnatural Products for $550m upfront.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
